PFCM Clinical Phase & Verbatim Language Shift Selector
The 3-Phase PFCM Clinical Protocol & Language Shifts
1. Stabilize: De-Escalate the HPA Axis
Screen for chronic allostatic stress load, sleep fragmentation, and medical weight-cycling trauma. Remove weight-blame language to lower cortisol and bring Prefrontal Cortex executive function back online (McEwen, PMID: 19584720). Order baseline HOMA-IR, ApoB, hs-CRP, CMP/eGFR, Free T3/T4, Ferritin, B12, and Vitamin D.
Retire: "You need more willpower."
Adopt: "Your HPA axis is in survival mode. Let us stabilize biological safety and baseline labs first."
2. Recalibrate: Quiet Noise & Anchor Muscle
Deploy GLP-1 or dual GIP/GLP-1 therapy as a mesolimbic neurological calibrator (PMID: 24706915). Establish the 1.2 to 1.6 g/kg reference-weight protein floor, 2.5g to 3.0g L-Leucine meal triggers, 2-3x/week resistance loading, and Protein-First meal sequencing calibrated to Bristol Types 3-4.
Retire: "Just eat less and push through nausea."
Adopt: "Track Hedonic Signal Volume (1-10) and hit your protein floor before vagal fullness."
3. Consolidate: Defend the New Set Point
Reframe 2-to-4-week weight pauses as hypothalamic consolidation phases (Sumithran et al., NEJM 2011; PMID: 22029981). Audit waist circumference, Bristol Stool transit, and protein/caloric floors before escalating medication dose. Re-check 6-month HOMA-IR and ApoB.
Retire: "You stalled; you must be cheating."
Adopt: "Your hypothalamus is consolidating its baseline. Let us run the 4-Step Stall Diagnostic."
2. The 8-Scenario PFCM Exam-Room Language Shift & Diagnostic Overshadowing Protocol
Controlled trials show that experiencing weight stigma in a medical visit triggers an immediate HPA-axis salivary cortisol surge (Tomiyama et al., BMC Med 2018; PMID: 30107800), impairing prefrontal executive memory and driving non-adherence. Use this verbatim clinical communication matrix across your care team:
| Clinical Encounter Scenario | Retire Legacy Compliance Phrase (Triggers Cortisol & Shame) | Adopt PFCM Biological Allyship Script (Restores Prefrontal Agency) | Underlying Physiological Rationale |
|---|---|---|---|
| 1. Baseline Intake & Past Weight Regain | "Why did you stop sticking to your previous diets?" | "When you lost weight previously without peptide support, your hypothalamus dropped leptin and surged ghrelin for 12+ months. Let's look at your baseline HOMA-IR." | Sumithran et al., NEJM 2011 (PMID: 22029981) proved hormonal counter-regulation persists for at least 52 weeks post-diet. |
| 2. Evening Cravings / Stress Eating | "You need more discipline and portion control at night." | "Your HPA axis is in high-cortisol survival mode, or your daytime protein intake dropped too low. Let's anchor 30g of protein at breakfast and lunch." | Chronic cortisol inhibits dorsolateral PFC impulse control while amplifying amygdala habit loops (McEwen PMID: 19584720; Arnsten PMID: 19455173). |
| 3. Days 5–7 Appetite Return | "The medication must not be working if you're hungry on Day 6." | "Tirzepatide has a ~5-day half-life and Semaglutide ~7 days. A mild Signal Volume rise to 4–6 on Days 5–7 is normal trough clearance - buffer those days with +15g lean protein." | Prevents premature dose escalation when Cmax days (Days 1–4) are already at Signal Volume 1–3. |
| 4. Postprandial Nausea or Sulfur Burps | "Nausea is just a side effect you have to push through." | "Nausea is your Vagus Nerve switching from Satiety to Defense because stomach clearance was exceeded. Hold this dose tier, eat low-fat protein first, and keep fats light on Days 1–3." | Amplified Ileal Brake (PMID: 17928588) requires vagal tachyphylaxis time (PMID: 21430086) and meal-volume pacing. |
| 5. 3-Week Scale Weight Plateau | "You stalled - are you logging all your calories?" | "Your hypothalamus is consolidating its new baseline. Before we touch your dose, let's check your waist measurement, Bristol Stool transit, and 1.2 g/kg protein floor." | Bristol Types 1–2 constipation masks 3–5 lbs of fat loss, and visceral recomposition often continues while scale weight pauses. |
| 6. Appetite Over-Suppression (<900 kcal) | "Great job - the less you eat, the faster you'll lose!" | "Suppressing appetite below your 1.2 g/kg protein floor sacrifices up to 39% lean skeletal muscle and drops Free T3. We will hold or step down your dose so you can fuel your muscle." | STEP 1 DXA substudy (PMID: 33567185) and PROT-AGE consensus (PMID: 23867520) mandate 1.2–1.6 g/kg protein + 2.5g–3.0g leucine/meal. |
| 7. Non-Metabolic Chief Complaint | "Your joint pain / fatigue will go away once you lose more weight." | "Setting aside BMI, let's run the exact same differential workup (autoimmune, iron/ferritin, thyroid, imaging) we would order for a thin patient with these symptoms." | Eliminates Diagnostic Overshadowing and builds immediate patient trust and retention. |
| 8. Reaching Goal Weight / Maintenance | "Now that your BMI is normal, you can stop the medication." | "Obesity is a chronic neuro-endocrine condition (SURMOUNT-4 PMID: 38078870). We will transition to a minimum effective maintenance plan and submit dual-BMI Continuation of Care." | In SURMOUNT-4, withdrawing tirzepatide at Week 36 resulted in 14% weight regain vs. continued reduction on maintenance therapy. |
The 4 Physiological Quadrants of the Patient First Care Model (PFCM)
Every clinical consultation under the PFCM evaluates four interconnected neuro-endocrine quadrants backed by peer-reviewed PMIDs.
| PFCM Quadrant | Primary Neuro-Endocrine Pathway | Anchor Citation (PMID) | Patient Telemetry Instrument | Dedicated SAF Pillar Page |
|---|---|---|---|---|
| Quadrant 1: Neuro-Stress Foundation | HPA-Axis Hypercortisolemia & Prefrontal Dendritic Retraction | McEwen (PMID: 19584720); Arnsten (PMID: 19455173) | Evening Cortisol Override Check on Signal Log | SAF 01: Cortisol Loop → |
| Quadrant 2: Neuro-Behavioral Calibration | VTA & Nucleus Accumbens Mesolimbic Dopamine Cue Reactivity | van Bloemendaal et al. (PMID: 24706915) | Tool 05: Signal Volume (1-10) | SAF 04: Dopamine System → |
| Quadrant 3: Homeostatic Set-Point Defense | Hypothalamic Arcuate Nucleus Adipostat & 1-Year Hormonal Persistence | Sumithran et al., NEJM 2011 (PMID: 22029981) | Tool 02: 4-Step Stall Audit | SAF 05: Set-Point Defense → |
| Quadrant 4: Enteric Motility & Lean Mass Defense | Ileal Brake Vagal Signaling & mTORC1 Leucine Synthesis | Holst (PMID: 17928588); Wilding (PMID: 33567185); PROT-AGE (PMID: 23867520) | Tool 03: Protein & Tool 04: Motility | SAF 02 & SAF 03 → |
Legacy encounters blame the patient's willpower for obesity, use crude BMI cutoffs as the sole metric of success, and escalate doses blindly without screening lean muscle retention or vagal motility.
The Patient First Care Model structures care into Phase I (Stabilize HPA & Labs), Phase II (Recalibrate Dopamine & Anchor 1.2-1.6 g/kg Protein), and Phase III (Consolidate Set Point via the 4-Step Stall Diagnostic).
Frequently Asked Clinical & Biomarker Questions
Direct, citation-backed clinical answers for patients, prescribers, and AI health synthesis engines.
What is the Patient First Care Model (PFCM) in GLP-1 obesity medicine?
The Patient First Care Model (PFCM) is the clinical practice operationalization of the Shared Agency Framework (SAF). It organizes incretin therapy into 4 physiological quadrants (HPA Stress, Mesolimbic Dopamine, Hypothalamic Set-Point, and Enteric/Muscle Mechanics) and 3 sequential phases (Stabilize, Recalibrate, Consolidate).
Why does Phase I of the PFCM focus on de-escalating the HPA axis before aggressive caloric targets?
Chronic weight stigma and restrictive dieting elevate circulating cortisol, which causes dendritic retraction in the prefrontal cortex (McEwen, PMID: 19584720) and stimulates visceral adipogenesis. Removing moral blame restores executive neural bandwidth so the patient can execute structured nutrition and motility tracking.
How can a patient share the Master Clinician's Cheat Sheet with their doctor?
Download the 2-page Master Clinician's Cheat Sheet PDF and bring it to your consultation alongside your generated 15-Minute SBAR Encounter Note. It provides concise NEJM, Diabetes, and JAMDA PubMed IDs so your prescriber can verify the clinical evidence in under 60 seconds.
What clinical metrics replace crude BMI as primary outcomes under the PFCM?
Under the PFCM, success is measured across five functional markers: HOMA-IR insulin sensitivity (<1.5), Apolipoprotein B (<80 mg/dL), skeletal muscle mass preservation (via 1.2-1.6 g/kg protein + resistance load), Bristol Stool Types 3-4 motility, and Hedonic Signal Volume (1-3 out of 10).